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ABSTRACT
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor with 
poor survival. Cytoreduction in association with radiotherapy and temozolomide (TMZ) 
is the standard therapy, but response is heterogeneous and life expectancy is limited. 
The combined use of chemotherapeutic agents with drugs targeting cell metabolism 
is becoming an interesting therapeutic option for cancer treatment. Here, we found 
that metformin (MET) enhances TMZ effect on TMZ-sensitive cell line (U251) and 
overcomes TMZ-resistance in T98G GBM cell line. In particular, combined-treatment 
modulated apoptosis by increasing Bax/Bcl-2 ratio, and reduced Reactive Oxygen 
Species (ROS) production. We also observed that MET associated with TMZ was able 
to reduce the expression of glioma stem cells (GSC) marker CD90 particularly in T98G 
cells but not that of CD133. In vivo experiments showed that combined treatment 
with TMZ and MET significantly slowed down growth of TMZ-resistant tumors but did 
not affect overall survival of TMZ-sensitive tumor bearing mice. In conclusion, our 
results showed that metformin is able to enhance TMZ effect in TMZ-resistant cell 
line suggesting its potential use in TMZ refractory GBM patients. However, the lack 
of effect on a GBM malignancy marker like CD133 requires further evaluation since 
it might influence response duration.
INTRODUCTION
Temozolomide (TMZ), used as standard therapy for 
glioblastoma multiforme (GBM) [1], is an alkylating agent 
that exerts its antitumor action through the methylation 
of DNA. TMZ is particularly effective against GBM 
tumors lacking the expression of DNA repair enzyme, 
O6-methylguanine-DNA methyltransferase (MGMT), 
which antagonizes the effect of alkylating agents. 
However, also MGMT-methylated tumors have been 
shown to finally become TMZ-resistant [2–4] and despite 
some initial response, GBM prognosis is poor and novel 
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therapeutic strategies are largely needed. A number of 
targeted therapies administered alone or in combination 
is under evaluation. However, most of these drugs act on 
pathways that are heterogeneously expressed in tumors 
and this limits their efficacy [5]. A common hallmark of 
GBM is represented by an aberrant metabolic phenotype 
characterized by increased glucose demand and aerobic 
glycolysis (the so called Warburg effect) [6]. According 
to recent evidences, high glucose energy demand favors 
glioma stem cells (GSC) survival, through the expression 
of high affinity glucose transporter 3 (GLUT3) in these 
cells [7]. Indeed, enhanced glycolysis and over expression 
of glucose transporters, particularly GLUT3 and 
hexokinase II represent negative prognostic factors for 
patients with GBM [7, 8]. For this reason, targeting of cell 
metabolism represents an attractive therapeutic strategy 
for GBM [9].
Adenosine Monophosphate-Activated Protein 
Kinase (AMPK) is a key regulator of cell energy status 
that influences cell growth, proliferation, protein and fatty 
acid synthesis and malignant transformation [10]. AMPK 
is activated by alkylating agents including TMZ and its 
activation involves O6-methylguanine production [11, 12]. 
Metformin (MET), an AMPK modulator, is a biguanide 
commonly used as first line therapy for type II diabetes. 
The antineoplastic effect of MET has been recently 
evaluated in experimental subcutaneous model of GBM 
and in gliospheres showing a synergistic activity with 
TMZ [13, 14].
Molecular mechanism of MET is heterogeneous 
and not fully understood. MET affects metabolism either 
indirectly, acting on systemic levels of insulin or glucose, 
or directly, targeting energy related pathways. Indeed, it has 
been observed that MET reduces several factors that favor 
GBM progression such as cell metabolism, mitochondrial 
oxygen consumption and expression of Hypoxia Inducible 
Factor 1α (HIF-1α) [15]. In tumors, MET affects cell 
growth and survival, in particular blocking cell cycle 
progression in G0/G1, promoting cell death and inhibiting 
angiogenesis and tumor diffusion [16]. As previously stated, 
MET action is mainly associated with a direct or indirect 
activation of AMPK that leads to the down regulation of 
mTOR complex 1 (mTORC1). MET can also act on p53 
and down regulate mTORC1 with AMPK independent 
mechanisms involving the amino acid sensor Rag GTPase 
and REDD1, a hypoxia dependent mTORC1 inhibitor [17]. 
Moreover, MET influences cell energy also blocking the 
mitochondrial complex I with a mechanism which differs 
from that of rotenone as indicated by the inhibitory effect 
on ROS generation [18]. The control of the GSC population 
is considered a key challenge in GBM [19, 20]. MET given 
alone or in combination with TMZ has shown a preferential 
inhibition of GSC also in experimental GBM models [14, 
21–23]. It has been reported that in vivo administration of 
biguanides inhibits orthotopic tumor formation, by blocking 
stem-like glioma-initiating cells [22, 24].
Despite these promising results, antitumor effects of 
MET, particularly in TMZ-resistant glioma cells remain 
poorly documented. In this study, we investigated both 
the in vitro and in vivo effect of MET given alone or in 
combined treatment in the TMZ-sensitive U251 and in 
the TMZ-resistant T98G glioma cell lines. In particular, 
we focused our experimental investigation on the effects 
of MET on stem cells related markers, metabolism and 
apoptosis.
RESULTS 
In vitro MET treatment improved sensitivity of 
U251 and overcame T98G resistance to TMZ 
In order to determine the dose of TMZ able to 
discriminate U251 and T98G responsiveness, both cell 
lines were firstly exposed to different doses of TMZ for 
48 h(Supplementary Figure 1). and cell viability was 
determined by Trypan blue exclusion test. A TMZ dose of 
25 µM was defined as the optimal dose to distinguish drug 
sensitivity of the two cell lines (Figure 1A). Furthermore, 
to determine whether MET affects tumor cell proliferation 
or increases sensitivity to TMZ, U251 and T98G cells 
were treated for 24, 48 and 72h with MET, TMZ and 
their combination (Combo). U251 cells showed a time-
dependent progressive inhibition of cell growth that was 
particularly evident with TMZ or Combo treatment but 
also visible with MET at 72h (Figure 1B, left panel). 
As expected, T98G cells were not sensitive to TMZ. 
However, both MET and Combo significantly reduced cell 
proliferation (Figure 1B, right panel). While in U251 cells, 
the addition of MET to TMZ determined only an additive 
effect, in T98G cells MET synergistically acted with TMZ, 
triggering inhibition levels ranging from 34% (MET only) 
to 69% (Combo) at 48 h (Supplementary Figure 1).
MET or combo treatment increased Bax and 
Bad transcripts but not Bcl-2 
In order to assess the effect of the drugs on cell 
apoptosis, pro-apoptotic Bax and Bad and anti-apoptotic 
Bcl-2 genes were analyzed using Real time-PCR. In U251 
cells, TMZ treatment induced an increase in Bax and 
Bad transcripts that were significantly higher after the 
administration of MET or Combo treatment (Figure 1C). 
Furthermore, Annexin V levels detected by FACS analysis 
were higher in Combo treated cells compared to untreated 
cells (75 ± 24 vs 10.4 ± 4.4). In T98G TMZ resistant cell line, 
effect of MET or Combo was similar to that one observed 
after TMZ treatment for both Bax and Bad transcripts (Figure 
1C). However, COMBO treated cells showed an increase of 
Annexin V levels compared to control cells (35 ± 12 vs 13.3 
± 6.1). In both cases, no significant modulation of activated/
cleaved Caspase-3 was observed (data not shown).
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Finally, in both cell lines we did not observe a 
significant variation in Bcl-2 expression in all the drug 
regimens considered herein (Figure 1D). However, after 
Combo treatment, a deeper increase of Bax/Bcl-2 and Bad/
Bcl-2 ratio, in both cell lines compared to single treatments 
was observed (Table 1). 
MET and combo treatment differently 
modulated GBM markers exerting a preferential 
effect on CD90
To evaluate if MET could act on a specific 
population of GBM cells, we measured the effect of TMZ, 
MET or Combo on the relative abundance of two markers: 
CD133 and CD90. The former, although not selectively 
expressed in cancer related stem cells, contributes to 
treatment resistance and tumor formation; the latter is 
widely expressed by a variety of cancer stem cells and 
according to some authors also in GSC [25, 26].
A high percentage of U251 cells were CD133 
positive at baseline. Administration of MET significantly 
reduced CD133 positivity of U251 cells and this effect 
was higher than that one observed after TMZ or Combo 
treatment (Figure 2A). In T98G cells, we observed a 
low level of CD133 in untreated condition, but a TMZ 
dependent increase in CD133 that was even higher after 
MET co-administration. No effect was observed in 
MET treated cells. TMZ significantly increased CD90 
expressing cells in both cell lines but co-administration 
of MET reverted this effect (Figure 2B). When given 
alone, MET increased CD90 only in U251 cells. Similar 
data were also obtained using Real time-PCR supporting 
the increase of CD133 and CD90 mRNA transcription 
(Supplementary Figure 2A–2D).
To further understand if combined treatment could 
affect other glioma subpopulations markers, FACS 
analysis of CD44 and CD73 were performed on both 
U251 and T98G cells (Supplementary Figure 3). CD73 
modulates cell adhesion, migration and invasion [27] and 
contributes to local adenosinergic immune suppression 
by acting on infiltrating CD4+T lymphocytes [28]. CD44 
is mainly expressed by the mesenchymal subtype of 
GBM cells and seems to exert a crucial role in tumor 
initiation and progression [29, 30]. TMZ, but not MET, 
reduced the relative expression of CD73 only in U251 
cells (Supplementary Figure 3A and 3B). In addition, 
TMZ increased the relative abundance of CD44 in both 
cell lines, an effect that was not counteracted by drugs 
co-administration (Supplementary Figures 3C and 3D). In 
summary, MET reduced the relative expression of CD90 
and CD133, the latter only in U251, but it was not able to 
counteract for the selection of CD133 and CD44 induced 
by TMZ.
Finally, we also investigated Sox2, an oncogene 
which plays important roles in cancer stem cells (CSC) 
and in TMZ-resistance in glioma [31]. In U251-sensitive 
cell line, Real time-PCR analysis showed a significant 
decrease in Sox2 expression after COMBO treatment, 
8.8-fold, (p < 0.01), when compared to TMZ and control 
treatment. Moreover, in T98G-resistant cell line, we 
observed a huge increase in Sox2 expression after TMZ 
treatment (18-fold compared to control, p < 0.0002) that 
was significantly counteracted of 3.5-fold (p < 0.0001) by 
Combo treatment.
MET treatment reduced ROS levels but 
promoted the glycolytic phenotype of GBM cells 
Evidences in literature indicate that MET inhibits 
mitochondrial complex I but it does not increase reactive 
oxygen species (ROS) levels [15]. Here we confirmed this 
observation reporting a MET-dependent reduction of ROS 
levels and an impairment of TMZ-dependent up-regulation 
of ROS in both cell lines (Figure 3A).
To evaluate how TMZ, MET or Combo affected 
cell metabolism, we measured glucose and glutamine 
consumption related to lactate and glutamate secretion. 
Neither of cell lines showed significant metabolic changes 
due to TMZ alone administration. On the contrary, MET 
administration, alone or in association with TMZ, was 
accompanied by an increase in the rate of glucose uptake 
and lactate secretion in U251 cancer cells (Figure 3B left 
panel) as compared to T98G cells (Figure 3B right panel). 
Furthermore, we did not observe a significant effect of the 
drugs in glutamine uptake but we detected a slight increase 
of glutamate secretion in both cell lines associated with 
MET administration (Figure 3C).
Repeated in vivo administration of MET 
increased the sensitivity of T98G model to TMZ
To test if MET was able to revert resistance of T98G 
cells to TMZ and to increase the response of U251 cells 
when administered in vivo, we compared the efficacy of 
TMZ administered alone to that of TMZ in combination 
with 250 mg/kg i.p. MET in both GBM models. This dose 
of MET was selected on the basis of previous reports [32] 
and on the lethal toxicity observed with higher doses. In 
general, TMZ and MET association was well tolerated. 
In the first days of therapy, TMZ induced a transient 
reduction of mouse weight, which was exacerbated by 
the addition of MET, but weight was rapidly recovered 
in the following days. U251 vehicle mice lost their 
weight due to tumor progression (Supplementary Figure 
4B and 4C). TMZ alone or Combo were administered 
in mice bearing intracranial U251 GBM cells and their 
effects were monitored in vivo using MRI. A progressive 
reduction in tumor volume growth was observed in mice 
treated with TMZ independently from MET (Figure 
4A). TMZ in combination and TMZ alone triggered a 
comparable reduction of tumor volume (-39.0 ± 29.3% 
and -35.9 ± 24.6% respectively) compared to vehicle 
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(+30.4%) as depicted by MRI analyses performed 7 days 
after treatment (Figure 4A and Supplementary Figure 
4A). Both treatment regimens displayed a similar efficacy 
at day 21: -62.9 ± 27.3% and -69.5 ± 17.8% in Combo 
and TMZ, respectively. At 41 days, a marked increase 
in tumor volume was observed in the majority of mice, 
except for two animals treated with Combo showing an 
arrest of tumor growth at MRI. In an additional group 
of mice treated with MET alone, we did not observe 
any significant difference compared to mice treated with 
vehicle (data not showed). Ex vivo IHC analyses showed 
a significant decrease in CD133 marker in Combo group 
compared to untreated group (p = 0.028), confirming in 
vitro results (Figure 2A and Figure 4B), but no difference 
was observed compared to TMZ treated group. However, 
no significant difference between TMZ and Combo groups 
in the expression of Ki67 and Nestin was observed (Figure 
4B and Supplementary Figure 5A).
As expected, in T98G tumor bearing mice, TMZ 
treatment was not able to reduce tumor growth. On the 
contrary, we observed a synergistic effect of TMZ in 
association with MET as indicated by the significant 
reduction in tumor growth rate in Combo group (TGI 
increased from 11% to 52%). The group of mice treated 
with MET showed a transient reduction in the rate of 
tumor volume increase similar to that observed for Combo 
animals, but only during the first week of treatment 
(Figure 4C).
In IHC performed on samples obtained at 21 days, 
we observed a significant increase in Ki67 marker in 
Combo group compared to vehicle probably anticipating 
a relapse of tumor growth (p = 0.0043) (Figure 4D and 
Supplementary Figure 5B). Nestin and CD133 were 
similarly expressed in control and Combo groups.
To further investigate the impact of treatment on 
in vivo metabolism remodeling, we performed metabolic 
profile of tumors using gas-chromatography-mass 
spectrometry technique. Metabolomics statistical analysis 
was performed using a mass profiler professional t-test 
and the result of the analysis represented significant 
metabolites in hierarchical clustering showing similar 
abundance values considering the minimum (blue 
color) and maximum (red color) color scale within a 
tree structure. The untargeted post mortem metabolic 
profiling of U251 mouse model showed, in treated 
animals, a notable metabolites set enrichment related 
to amino acids, fatty acids and lipids metabolism. In 
addition, analysis displayed a significant reduction of 
32 metabolites in Combo when compared to TMZ alone 
(Supplementary Figure 6A). The metabolic profiling 
performed post mortem in T98G tumor mouse model 
identified significant differences between TMZ alone and 
Combo in 8 compounds belonging to nucleotides, amino 
acids, glutathione, lipids, amino sugar and β-alanine 
metabolism (Supplementary Figure 6B). Finally, to 
confirm the different effect of drugs in the two mouse 
models, we compared the metabolic profile of the two 
groups of animals including treatment effects. The 
untargeted metabolic profiling indicated a significant 
reduction of metabolites in U251 mice in comparison with 
T98G independently from treatment, and this reduction 
concerned metabolites belonging to nucleotide and amino 
acids pathway (Figure 5A–5B).
DISCUSSION
In the present work, we investigated the effect of 
metformin, a first line antidiabetic drug with promising 
anticancer effects on GBM models, when given alone or 
in association with TMZ-based standard chemotherapy. 
To this aim, treatment effects were evaluated in vitro and 
in vivo in two GBM models characterized by different 
MGMT methylation status and TMZ sensitivity. Recent 
evidences suggest that MET is able to i) modulate 
anabolic metabolism, inducing cell cycle arrest and 
cell death [13, 33]; ii) reduce GSC cells, increasing the 
treatment sensitivity [22] and iii) improve responsiveness 
of glioma cells to TMZ treatment, counteracting the 
MGMT presence [13]. The efficacy of combining MET 
and the alkylating agent TMZ in GBM has been already 
proposed [34] since it increases AMPK activation. In 
addition, according to published data, combined treatment 
with TMZ and MET exerts a greater inhibition on glioma 
cancer stem cells compared to single agents [14, 21]. 
Table 1: Bax and Bad to Bcl-2 ratios in U251 and T98G cell line
Cell line Treatment Bax/Bcl-2 Bad/Bcl-2 P value
 (vs control)
U251
TMZ 16.09 ± 2.5 11.8 ± 3.6 0.05
MET 28.8 ± 3.6 26.4 ± 2.6 0.05
TMZ + MET 58.6 ± 2.5 35.6 ± 2.5 0.001
T98G
TMZ 9 ± 1.5 10.0 ± 2.2 0.05
MET 9 ± 2.2 8.0 ± 1.8 0.05
TMZ+MET 18 ± 3.0 20.0 ± 2.6 0.05
TMZ + MET vs single treatments p < 0.001
Data are expressed as mean ± SD.
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Based on these observations, we further investigated 
in vitro and in vivo the effect of MET given alone or in 
combination in the TMZ-sensitive U251 GBM cells and 
explored its potential efficacy on the TMZ-resistant T98G 
GBM cells. In vitro we showed that MET reduced growth 
rate of both U251 and T98G cells with an additive effect 
for the former and a synergistic one for the latter when 
given in association with TMZ.
Both TMZ and MET modulated pro- and anti-
apoptotic genes without affecting Caspase-3 activation. 
Although a clear mechanism for MET-induced apoptosis 
has not been clarified, Zhuang et colleagues have already 
demonstrated that in MET-sensitive cancer cell lines, 
cell death was mediated by both caspase-dependent and 
-independent mechanisms, these last involving poly(ADP-
ribose) polymerase (PARP) [35]. Our results showed that 
the increase in the regulation of pro-apoptotic genes, 
detected especially in TMZ-sensitive cells, was not 
caspase-dependent, since the levels of cleaved Caspase-3 
were not affected by treatments (data not shown). 
In parallel, we observed a down-regulation of Bcl-2 
associated to an increase of Bax resulting in a significant 
increase of Bax/Bcl-2 ratio.
Oxidative stress triggered by chemotherapeutic 
agents, as TMZ, is considered a putative mediator 
of apoptosis [36]. We observed an increase of ROS 
production after TMZ treatment (Figure 3A) but only in 
U251 cell line. On the contrary, the addition of MET to 
TMZ leads to a decrease of ROS both in TMZ-sensitive 
and in -resistant cell line. It has been previously observed 
that MET inhibits mitochondrial ROS production, a 
mechanism that has been related to the blockage of 
the reverse electron flow through the respiratory chain 
complex I [18, 37, 38]. Dysfunction of the respiratory 
chain complex I could exacerbate metabolic need and 
Warburg effect. Regarding this effect, we found that the 
use of MET alone and in combination with TMZ also 
induced significant changes in glucose metabolism in both 
cell lines. In particular, it prompted a higher consumption 
of glucose and a higher release of lactate in cell culture 
(Figure 3B) indicating that MET exacerbates Warburg 
effect as previously observed [13, 23].
This metabolic reprogramming is an index that 
cells are more susceptible to the lack of energy supply. 
Glutamine could represent an alternative energetic 
substrate to fuel cancer cells. After MET administration, 
we observed a slight increase of glutamate levels in 
extracellular medium of T98G cells but no modification 
in glutamine uptake. This last observation is not surprising 
since GBM can produce glutamine from intracellular 
glutamate through the activity of glutamine synthetase and 
glutamate is released outside cells also during glutamine 
starvation [39]. Glutamate release occurs via Xc system, 
a cysteine-glutamate exchanger that imports cysteine for 
the synthesis of the cellular antioxidant glutathione (GSH) 
and protects cells from cytotoxic intracellular glutamate 
levels [40, 41]. On the other hand, it is well known that a 
significant increase in the quantity of glutamate released 
in the extracellular space contributes to excitotoxicity and 
consequent glioma expansion in the peri-tumoral space 
[40]. The increased outflow observed in T98G cells may 
occur to prevent a potential glutamate overload due to the 
reduction of anabolic processes induced by MET.
A large number of evidences showed that MET 
affects GSC proliferation, self-renewal capabilities 
and survival with a higher efficiency compared to 
differentiated glioma cells [14, 23]. In the present study, 
we focused our attention on different putative negative 
prognostic markers of GBM linked with GSC or GIC 
(glioma initiating cells): CD133, CD90 and CD44. CD133 
is largely used as a negative prognostic CSC marker 
in several tumors, including GBM [42], although its 
function in normal and cancer stem cell is not definitely 
understood. CD90, also known as Thy-1, is a heavily 
glycosylated glycophosphatidylinositol (GPI)-anchored 
cell surface protein that has been previously identified as 
a marker for several stem cells such as hematopoietic stem 
cells and bone marrow-derived mesenchymal stem cells. 
Nevertheless, its role in GSC is still under debate [43]. 
In any case, the expression of CD90 dramatically raises 
in case of tumor shift from low to III-IV grade glioma 
considering it a marker of high-grade brain malignancy. 
On the other hand, CD44 seems to exert a crucial role 
in tumor initiation and progression. Our in vitro results 
indicated that MET alone strongly decreased (in U251) 
or maintained stable (in T98G) the relative abundance of 
CD133 cells but not in Combo treatment where the effect 
of TMZ became prevalent. A similar result was observed 
also for the CD44 marker. On the contrary, MET was able 
to significantly counteract TMZ effect, decreasing the 
relative abundance of CD90 cells in Combo group both 
of U251 and T98G cells, suggesting a role of MET in the 
modulation of this population of cells independently from 
TMZ-sensitivity.
In our in vivo experiments, U251 cells confirmed 
their high sensitivity to TMZ, indeed TMZ alone was 
able to significantly reduce tumor volume until 21 
days from the beginning of therapy similarly to Combo 
treatment (Figure 4A). In U251 the effect of MET could 
be partially covered by the high dose of TMZ (400 mg/
kg) which we have chosen to compensate the absence of 
radiotherapy. Conversely, in T98G tumors TMZ alone 
didn’t cause any effect although the association of TMZ 
and MET was able to synergistically reduce the rate of 
tumor growth compared to control. Nevertheless, at day 21 
a relapse of tumor growth was visible in Combo tumors. 
In addition, also MET alone decreased tumor growth in 
the first 7 days of therapy. Metabolic analysis performed 
on tumor samples collected post mortem confirmed 
therapy modulation of tumor metabolism. Main effects 
were due to TMZ, indeed metabolomics analysis showed 
significant changes in amino acid, nucleotide and fatty 
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Figure 1: Temozolomide and metformin effects on U251 and T98G cells viability and apoptosis. (A) U251 and T98G cells 
were treated with increasing doses of TMZ (0–25 µM) for 48 hours. Cell viability was assessed by Trypan blue exclusion test and expressed 
as number of cells. (B) MET for 24, 48 and 72 h. Cell viability was assessed as previously described.U251 and T98G cells were treated 
with 25 µM TMZ and/or 10 mM MET for 24, 48 and 72 h. Cell viability was assessed as previously described. (C) Real time-PCR for pro-
apoptotic Bax and Bad genes 48 h after treatment with TMZ and/or MET. Data were normalized for β-actin and ΔΔct expressed as Fold Of 
Induction (FOI). (D) Real time-PCR for anti-apoptotic Bcl-2 gene 48 h after treatment with TMZ and/or MET. Data were normalized for 
β-actin and ΔΔct expressed as Fold Of Induction (FOI). Data are shown are mean ± standard deviation. *p < 0.05; ** p < 0.01; ***p < 0.001 
vs control sample (untreated cells). #p < 0.05 vs TMZ treatment.
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acid and lipid metabolism. In addition a higher response 
both to TMZ alone and to Combo was observed in U251 
tumors than in T98G ones (Figure 5A–5B) indicating a 
higher sensitivity of U251 to this therapy and a recover 
of growth of T98G tumors at 21 days. Stem cells markers 
could explain the lack of long-term effects exerted by the 
combined administration of the two drugs. MET showed a 
high effect on CD90 expressing cells, but it was not able to 
contrast the increase in the relative abundance of CD133 
and CD44 induced by TMZ. The time-dependent selection 
of these aggressive phenotypes could limit the duration 
of treatment efficacy even in presence of MET. On the 
other hand, other factors may affect the in vivo response. 
The human Organic Cation Transporters (OCT1, OCT2, 
OCT3), which are expressed on cell membrane, influence 
MET uptake in different tissue compartments including 
tumor. OCTs are synthesized in the cytoplasmic region and 
during time, due to the constant intracellular trafficking, 
are partially moved and inserted to the external membrane. 
A time-dependent reduction or miss-localization of OCT3 
has been reported in glioma cells orthotopically implanted 
in mice [44]. For these reasons, an involvement of the 
OCT family in the duration of MET effects cannot be 
excluded. In addition, tumor-associated inflammatory 
response is pivotal to support growth and invasion and 
could have an important role in chemoresistance [45]. 
New PET radiopharmaceuticals have been developed to 
detect the 18 kDa translocator protein TSPO which is 
expressed by most glioma cells and activated microglia 
[46]. Nevertheless, our athymic models limit the 
possibility to fully investigate the complex interaction 
between inflammation cells and glioma cells by underling 
the need to perform further studies in syngeneic models.
In conclusion, results of our study showed MET 
efficacy in reverting treatment resistance in a TMZ-
insensitive cell line as indicated by the in vitro and in 
vivo results on T98G cells model suggesting the potential 
usefulness of MET for the treatment of TMZ refractory 
GBM patients. In U251-TMZ sensitive cells we observed 
that MET alone or co-administered with TMZ is more 
effective than TMZ alone in vitro. However, when 
administered in vivo, differently to what previously 
showed in patients-derived GIC [22], MET was not able 
to block tumor growth or to potentiate the effects of a high 
dose of TMZ. Our results indicate that the in vivo effect of 
MET is cell line dependent and it may be transient. These 
observations stress the need for a further experimental 
development of MET in a large set of well-characterized 
GBM models.
MATERIALS AND METHODS 
Cell lines and reagents
The human U251 (kindly provided by Dr. G. 
Melillo, National Cancer Institute, Frederick, MD, USA) 
and T98G (ATCC, Manassas, VA, USA) glioblastoma cell 
lines were transfected to put the expression of mCherry 
protein under the control of PGK promoter. U251 and 
T98G cells were routinely maintained in RPMI or 
E-MEM medium supplemented with 10% heat-inactivated 
fetal bovine serum, penicillin and streptomycin (50 IU/
ml) and 2mM glutamine (Euroclone, UK). Cells were 
maintained in a humidified atmosphere of 5% of CO
2
 at 
37°C. U251 and T98G cells displayed a methylation of 
MGMT promoter of 65% and 40%, respectively measured 
using pyrosequencing analysis. In vitro treatments were 
performed as follows: 10,000 cells/cm2 were treated with 
different concentrations of TMZ (0.1, 1, 5, 10, 25 μM) 
and 10 mM of MET (both Sigma Aldrich, St. Louis, MO, 
USA) for 24, 48 and 72 hours (h). Cell viability was 
evaluated by Trypan blue exclusion test. The effect of 
MET and TMZ in combination was calculated considering 
cell growth inhibition measured as: [1 - (Cf / C0)A / (Cf / C0)
V)]
* 100 where Cf is the cell number at the point analyzed, 
C0 is the cell number at the beginning of treatment, A is the 
corresponding drug and V is the vehicle [47].
FACS analysis
Two hundred thousand (200,000) cells were washed 
in PBS and incubated with 0.5 µg of: CD90-FITC, human 
(clone: DG3)-FITC, human 130-095-403; Monoclonal 
CD133/2 (293C3)-FITC, human 130-090-853; CD44-
FITC, mouse (clone: IM7.8.1) 130-102-511; CD73-
PE, human (clone: AD2)-FITC, human 130-095-182 
(MiltenyiBiotec). For apoptosis, in the same cells FITC 
Annexin V apoptosis Detection Kit I (BD Pharmingen) 
was used to measure Annexin V levels.
Viable cells were gated by forward, side scatter and 
analyzed on 100,000 acquired events for each sample. 
Samples were analyzed on a PartecCyFlow Space using 
the PartecFloMax® software.
RNA extraction and real-time PCR
RNA was extracted using the commercially available 
illustra RNAspin Mini Isolation Kit (GE Healthcare, Italy), 
according to manufacturer’s instructions. Total RNA was 
reverse-transcribed to cDNA using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystem, 
USA). Real-time PCR was performed in duplicate for 
each data point and the oligonucleotides used were: beta-
actin (FRW: ATCAAGATCATTGCTCCTCCTGA, REV: 
CTGCTTGCTGATCCACATCTG); Bax (FRW: GAG AGG 
TCT TTT TCC GAG TGG; REV: CCT TGA GCA CCA GTT 
TGC TG); Bad (FRW: GTTCCAGATCCCAGAGTTTG; 
REV: CCTCCATGATGGCTGCTG); Bcl-2 (FRW: 
′TTGTGGCCTTCTTTGAGTTCGGTG, REV: 
GGTGCCGGTTCAGGT ACTCAGTCA); Sox 2 
(FRW: GCACATGAACGGCTGGAGCAACG; REV: 
TGCTGCGAGTAGGACATGCTGTAGG). Changes in the 
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target mRNA content relative to housekeeping (β-actin) were 
determined with the ΔΔct method.
Luminescence kit
U251 and T98G were treated as previously 
described and, after 48 h of incubation, were tested to 





directly in cell culture or in defined enzyme reactions. 
Relative luminescence units were detected using a plate 
reader (Glomax) and after protein normalization with 
Bradford assay, data were expressed as RLU (Relative 
Luminescence Units).
In vitro evaluation of cell metabolism
To evaluate metabolic changes in response to 
different drugs, cell medium has been analyzed after 
48 h therapies with 25 µM TMZ alone and/or 10 
mM MET alone and with vehicles. Glucose, lactate, 
glutamine and glutamate have been measured using 
YSI 2950 Biochemistry analyzer (YSI, Incorporated 
USA). Metabolites concentration has been normalized 
to that of original medium and then corrected for protein 
concentration measured with Bradford assay.
Mouse models
Animal experiments were carried out in compliance 
with institutional guidelines for the care and the use of 
experimental animals, which have been notified to the 
Italian Ministry of Health and approved by the Ethics 
Committee of the University of Milan and of IRCCS 
San Raffaele Scientific Institute of Milan. The orthotopic 
U251 glioma model was obtained by stereotaxic injection 
(coordinates: 1.5 mm lateral to the bregma, 0 mm behind, 
3.0 mm ventral to the dura) [48] of 1 × 105 glioma cells 
(U251-HRE-mCherry) in 2 µl of phosphate-buffered 
saline (PBS) into 7 to 8 weeks old female nude mice at 
day 0. To obtain the T98G glioma model, 7 to 8 weeks 
old female nude mice were subcutaneously (s.c.) injected 
on both flanks with 5 × 106 T98G cells mixed 1:1 with 
matrigel. After cells injection, mice were monitored every 
day for body weight and signs of illness and sacrificed at 
appearance of evident signs of illness or at loss of more 
than 15% of the initial weight.
Figure 2: Glioma stem cell marker modulation after treatments. FACS analysis for CD133 (A) and CD90 (B) markers in U251 
and T98G cells after 48 h of treatment with 25 µM TMZ and/or of MET. Data were expressed as percentage of positive cells on the number 
of total cells. Data are shown are mean ± standard deviation. **p < 0.01; ***p < 0.001 vs control sample (untreated cells). #p < 0.05; ###p < 
0.001 vs TMZ treatment.
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Animal treatments and monitoring
As previously observed, 21 days after cells injection 
mice bearing U251 cells showed visible tumors and 
treatments began [49]. TMZ (400 mg/kg as single dose) 
dissolved in 10% DMSO was administered alone by oral 
gavage as standard therapy (TMZ group, n = 7) and in 
association with MET (i.p. 250 mg/kg, daily for 21 days) 
dissolved in saline (Combo group, n = 8). Our TMZ dose 
was slightly higher than that one administered in adjuvant 
therapy in a 60 kg patient. Indeed adjuvant TMZ therapy 
consists of 1620 mg/cycle for a human of average weight. 
According to the surface area rule, our dose consists of 
1944 mg.
Tumor response was monitored using Magnetic 
Resonance Imaging (MRI) performed before starting 
treatments as well as after 7 and 21 days of treatment. 
After the end of therapy, mice were monitored to disease 
Figure 3: Metformin modulated ROS production and glucose and glutamine metabolism. (A) Luminescent assay applied 




) in cell culture medium of U251 and T98G after treatment with 25 µM TMZ and/or 10 
mM MET. Data were expressed as Relative Luminescence Units (RLU) obtained by luciferase counts normalized to amount of proteins 
quantified by Bradford assay. (B) Glucose lactate, (C) glutamine and glutamate were measured in cell medium after 48 h of therapy. Data 
are shown as mean ± standard deviation. *p < 0.05; **p < 0.01;***p < 0.001 vs control sample (untreated cells); #p < 0.05; ##p < 0.01; ###p < 
0.001 vs control sample; § p < 0.05 vs control sample (untreated cells).
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relapse and in presence of evident signs of illness, animals 
were sacrificed and brain removed for IHC analysis. A 
further group of mice was treated with vehicle (Control 
group, n = 4) and monitored for survival. For T98G model, 
when tumors were visible mice were randomly assigned 
to treatment groups (Vehicle, TMZ, MET and Combo) 
and tumor growth was evaluated twice a week using 
caliper following the formula V = (L × l2) / 2 where L 
is the longer side and l is the shorter one. Modifications 
in tumor volume were calculated using: TV = (Vt-V0) / 
V0
* 100 (where V0 is the tumor volume at the beginning 
of treatments and Vt is the volume at different times). 
Moreover, tumor growth inhibition (TGI) and the effects 
of treatment combination were calculated at the last time 
point according to Navarro et al. [47].
MRI study
Magnetic Resonance Imaging (MRI) was performed 
on a 7T preclinical magnetic resonance scanner (Bruker, 
BioSpec 70/30 USR, Paravision 5.1, Germany), equipped 
with 450 mT/m gradients (slew-rate: 3400–4500T/m/s; 
rise-time: 140 ms). A phased-array mouse-head coil with 
four phased-array channels was used as receiver, coupled 
Figure 4: MET and TMZ effects in in vivo glioma models. (A) Variation of U251 tumor volume measured at contrast-enhanced 
T1 MRI after treatment expressed as percentage of volume change. Error bars indicate SEM. (B) U251 derived orthotopic brain 
tumors from vehicle (CTRL), TMZ or TMZ/metformin (Combo) treated mice were analyzed for Ki67, Nestin and CD133 markers by 
immunohistochemistry. No difference between the tumor edge and bulk areas in IHC staining intensities or percentages of positive cells 
was observed for any of the investigated markers. H&E was performed for morphological evaluation of the tumors. Representative images 
are shown with original magnification x200. (C) Variation of T98G tumor volume measured using caliper after treatment expressed as 
percentage of volume variation. In T98G xenograft model already at 7 days, the combined treatment significantly slowed down tumor 
growth compared to control (p value = 0.005), moreover a transient reduction was observed with MET (p value = 0.03). After 3 weeks, 
only Combo-treated mice displayed tumor smaller than vehicle (p value = 0.04). Error bars indicate SEM. (D) T98G tumors from vehicle 
(CTRL), TMZ, MET or TMZ/metformin (Combo) treated mice, were analyzed for Ki67, Nestin and CD133 markers expression by 
immunohistochemistry. No difference between the tumor edge and bulk areas in IHC staining intensities or percentages of positive cells 
was observed for any of the investigated markers. Hematoxylin and eosin staining (H&E) was performed for morphological evaluation of 
the tumors. Representative images are shown with Original magnification x200.
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Figure 5: Comparison of drug metabolic effects in in vivo glioma models. (A) Metabolic profiling comparison between in 
vivo U251 and T98G samples treated with TMZ by t-test statistical analysis. (B) Metabolic profiling comparison of in vivo U251 and 
T98G samples treated with TMZ plus MET by t-test statistical analysis. T-test statistical analysis was performed using MPP software. The 
dendrogram was produced by applying a hierarchical clustering algorithm. The legends color range was automatically generated by MPP, 
considering the minimum and maximum values of most compounds identified to highlight the best differences between samples through 
the most suitable color scale.
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with a 72 mm linear-volume coil as transmitter. Mice 
were anesthetized with isoflurane (2% in oxygen) and 
positioned prone on a dedicated heated apparatus, to 
prevent hypothermia. A coronal 2D High Resolution (HR) 
Rapid Acquisition with Relaxation Enhancement (RARE) 
T2 [repetition time (TR) = 3200 ms; echo time (TE) = 
38 ms; rare factor = 8; field of view (FOV) = 14000 mm; 
matrix = 256; slice thickness/inter-slice distance = 0.6 × 
0.6 mm] and a RARE T1 [TR = 438.088 ms; TE = 7.28 
ms; rare factor = 2; FOV = 20000 mm; matrix = 170] were 
acquired. After the injection of 0.2 µl/g of gadobutrol 
(Gadovist, Bayer Schering Pharma, Berlin-Wedding, 
Germany), acquisition of the RARE T1 was repeated. 
Tumor volume was calculated by manual contour of the 
post-contrast RARE T1 sequence by a neuroradiologist 
with 16 years of experience in preclinical MR imaging.
Immunohistochemistry
At sacrifice, brains were collected, fixed in 10% 
neutral buffered formalin (Sigma-Aldrich) and paraffin 
embedded. Standard haematoxylin and eosin (H&E) 
staining was performed for morphological evaluation.
The following specific primary antibodies were 
used for immunohistochemistry (IHC) experiments: 
HIF-1α (clone54, dilution 1:200, BD Transduction 
Laboratories, San Diego, CA, USA), Ki-67 (30–9 
CONFIRM, dilution1:100, Ventana Medical Systems 
Inc., Tucson, AZ, USA), CD133 (AC133, Miltenyi Biotec, 
Bergisch Gladbach, Germany) and Nestin (MAB1259, 
dilution 1:4000, R&D Systems, Minneapolis, MN, 
USA). IHC was performed using an automatic stainer 
(BenchMark ULTRA, Ventana Medical Systems Inc.), 
with diaminobenzidine (DAB ultraView, Ventana 
Medical Systems Inc.) as chromogen, and finally slides 
were counter stained with haematoxylin. As negative 
controls, one slide per antibody was incubated only with 
secondary antibody and detection reagents. All slides were 
digitalized using Aperio Digital Pathology slide scanner 
(Leica Biosystems, Milan, Italy) at 20x magnification. 
Immunoreactivity for cytoplasmic (Nestin), membranous 
(CD133), or nuclear (Ki67) localization in the various 
samples was evaluated and scored using an automated 
algorithm implemented in ImageScope software (Leica 
Biosystems), in terms of percentages of positive cells. 
Metabolite profiling in tissue samples
Tissue metabolite extraction and derivatization 
were performed as described in Gaglio et al. [50]. GC/MS 
analysis was performed using 7200 accurate-mass Q-TOF 
GC/MS (Agilent Technologies) equipped with a 40-m DB-
35MS capillary column operating under electron impact 
(EI) ionization at 70eV. Samples (1 μl) were injected in 
a splitless mode at 250°C, using helium as the carrier 
gas at a flow rate of 1 ml/min. The GC oven temperature 
was held at 100°C for 2 min and increased to 325°C at 
10°C/min. GC/MS data processing was performed using 
Agilent Muss Hunter software and statistical analyses 
were performed using Mass Profiler Professional (MPP) 
software.
Statistical analysis
In vitro experiments were repeated three times, 
giving reproducible results. Whole data are shown as 
mean values ± standard deviation (SD) or standard error 
of the mean (SEM) as indicated. T-test, one- or two-way 
analysis of variance (ANOVA) followed by Dunnett’s test 
or Mann-Whitney U test, were performed using Prism 4 
(GraphPad Software Inc., CA, USA).
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